Affordable Access

deepdyve-link
Publisher Website

In vitro diagnostics of coronavirus disease 2019: Technologies and application.

Authors
  • Lai, Chih-Cheng1
  • Wang, Cheng-Yi2
  • Ko, Wen-Chien3
  • Hsueh, Po-Ren4
  • 1 Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, Taiwan. , (Taiwan)
  • 2 Department of Internal Medicine, Cardinal Tien Hospital and School of Medicine, College of Medicine, Fu Jen Catholic University, New Taipei City, Taiwan. , (Taiwan)
  • 3 Department of Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan. , (Taiwan)
  • 4 Department of Laboratory Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan. Electronic address: [email protected] , (Taiwan)
Type
Published Article
Journal
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi
Publication Date
Apr 01, 2021
Volume
54
Issue
2
Pages
164–174
Identifiers
DOI: 10.1016/j.jmii.2020.05.016
PMID: 32513617
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Laboratory-based diagnostic measures including virological and serological tests are essential for detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Real-time reverse transcription-polymerase chain reactions (rRT-PCR) can detect SARS-COV-2 by targeting open reading frame-1 antibodies (ORF1ab), envelope protein, nucleocapsid protein, RNA-dependent RNA polymerase genes, and the N1, N2, and N3 (3N) target genes. Therefore, rRT-PCR remains the primary method of diagnosing SARS-CoV-2 despite being limited by false-negative results, long turnaround, complex protocols, and a need for skilled personnel. Serological diagnosis of coronavirus disease 2019 (COVID-19) is simple and does not require complex techniques and equipment, rendering it suitable for rapid detection and massive screening. However, serological tests cannot confirm SARS-CoV-2, and results will be false-negative when antibody concentrations fall below detection limits. Balancing the increased use of laboratory tests, risk of testing errors, need for tests, burden on healthcare systems, benefits of early diagnosis, and risk of unnecessary exposure is a significant and persistent challenge in diagnosing COVID-19. Copyright © 2021. Published by Elsevier B.V.

Report this publication

Statistics

Seen <100 times